DNAY CODEX DNA INC

Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, August 9, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.

The press release and live audio webcast can be accessed via the Investors section of Codex DNA’s website at . The conference call can be accessed by registering at the following link: . Please log in approximately 5 to 10 minutes before the event to ensure a timely connection. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. A replay of the conference call webcast will be archived on the Codex DNA's website for at least 30 days.

About Codex DNA

Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Codex DNA, the Codex DNA logo, Gibson Assembly, and BioXp are trademarks of Codex DNA Inc.

Contact:

Brent Hunter

Vice President of Finance

(815) 780-0842



EN
02/08/2022

Underlying

DNAYCODEX DNA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CODEX DNA INC

 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutio...

Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio’s Gibson SOLA enzymatic reagent platform running on Bec...

September 25, 2024 1 EN
 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Marke...

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.001 per share (the “Common Stock”) and deregister the Common Stock under S...

September 10, 2024 1 EN
 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Reports Second Quarter and First Half 2024 Financial Resul...

Telesis Bio Reports Second Quarter and First Half 2024 Financial Results SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity lo...

August 7, 2024 1 EN
 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Reports First Quarter 2024 Financial Results

Telesis Bio Reports First Quarter 2024 Financial Results SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024.  In discussing results, recently appointed President and CEO Eric Esser said, “I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA off...

May 9, 2024 1 EN
 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Announces Reverse Stock Split

Telesis Bio Announces Reverse Stock Split SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced that it will effect a 1-for-18 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on Thursday, May 9, 2024, and the Company's common stock will open for trading on The Nasdaq Global Select Market on May 9, 2024 ...

May 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch